-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 I7bKKnOc4Lu80oMZZjc8rjF6cBscxwJckcPIstvOnjBR9O4I6PrImMHa5X+Y5cdv
 ucri9upW6A5fF9N9t9GYRw==

<SEC-DOCUMENT>0001157523-09-004213.txt : 20090529
<SEC-HEADER>0001157523-09-004213.hdr.sgml : 20090529
<ACCEPTANCE-DATETIME>20090529145343
ACCESSION NUMBER:		0001157523-09-004213
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090529
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20090529
DATE AS OF CHANGE:		20090529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		09861044

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a5976108.txt
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       the Securities Exchange Act of 1934


         Date of Report (Date of Earliest Event Reported): May 29, 2009


                            Anika Therapeutics, Inc.
- --------------------------------------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

         Massachusetts              000-21326               04-3145961
- --------------------------------------------------------------------------------
    (State of Incorporation)       (Commission           (I.R.S. Employer
                                   File Number)         Identification No.)

32 Wiggins Avenue, Bedford, Massachusetts                       01730
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices)                      (Zip Code)


Registrant's telephone number, including area code:        (781) 457-9000
                                                    ----------------------------



- --------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]    Written communications pursuant to Rule 425 under the Securities Act (17
       CFR 230.425)

[ ]    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
       CFR 240.14a-12)

[ ]    Pre-commencement communications pursuant to Rule 14d-2(b) under the
       Exchange Act (17 CFR 240.14d-2(b))

[ ]    Pre-commencement communications pursuant to Rule 13e-4(c) under the
       Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Item 8.01     Other Events.

Following its review of the recent RiskMetrics Group analysis of the proposals
to be submitted to stockholders at the Anika Therapeutics, Inc.'s (the
"Company") 2009 Annual Meeting of Stockholders, the Company's Board of
Directors, on May 29, 2009, approved an amendment to the Anika Therapeutics,
Inc. Amended and Restated 2003 Stock Option and Incentive Plan (the "2003 Stock
Plan") to reduce the proposed increase in the number of shares subject to the
2003 Stock Plan from 1,000,000 to 850,000, which will result in a total of
2,350,000 shares of common stock being reserved for issuance under the 2003
Stock Plan. The proposed 850,000 share increase will reduce the potential
dilutive impact of the 2003 Stock Plan on other stockholders as compared to the
originally proposed 1,000,000 share increase. The 2003 Stock Plan, as so amended
and restated, remains subject to stockholder approval at the 2009 Annual Meeting
of Stockholders to be held on Friday, June 5, 2009.


<PAGE>

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                       ANIKA THERAPEUTICS, INC.

Dated: May 29, 2009                    By: /s/ KEVIN W. QUINLAN
                                           -------------------------------------
                                           Kevin W. Quinlan
                                           Chief Financial Officer
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
